Trial Profile

A Phase II Randomized Study of Pegylated Liposomal Doxorubicin, Cyclophosphamide Versus Epirubicin-Cyclophosphamide as Adjuvant Chemotherapy in Her2-negative Stage I and II Breast Cancer Patients

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Epirubicin
Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer
Focus Biomarker; Therapeutic Use
Sponsors TTY Biopharm

Most Recent Events

13 Sep 2022 Interim Results (December 31, 2020)presented at the 47th European Society for Medical Oncology Congress
22 Nov 2021 Planned End Date changed from 1 May 2023 to 31 Oct 2022.
22 Nov 2021 Planned primary completion date changed from 1 Oct 2019 to 31 Oct 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com